• 22
  • 2
  • 收藏

Angion shares drop 56% as kidney transplant drug misses endpoint in late-stage trial

seekingalpha2021-10-27

ANG-3777, a drug for kidney transplant patients at risk for developing delayed graft function from Angion Biomedica(NASDAQ:ANGN)and Vifor Pharma,did not meet its primary endpoint in a phase 3 trial. ...

网页链接

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

举报

评论2

  • Vin309
    ·2021-10-27
    Wt
    回复
    举报
  • chefbean
    ·2021-10-27
    Hee
    回复
    举报
 
 
 
 

热议股票

 
 
 
 
 

7x24